Results 111 to 120 of about 3,031 (200)

Wet-Cupping's Impact on Pancreatitis Induced by Hypertriglyceridemia: A case study and brief literature review. [PDF]

Sultan Qaboos Univ Med J
Al Saadi W, Al Balushi AS, Al Mukhaldi A, Al Farhan H, Al Alawi AM.   +4 more
europepmc   +1 more source

Prevalence and Influence of Genetic Variants on Follow-Up Results in Patients Surviving Thoracic Aortic Therapy. [PDF]

J Clin Med
Ghazy T, Elzanaty N, Lackner HK, Irqsusi M, Rastan AJ, Behrendt CA, Mahlmann A.   +6 more
europepmc   +1 more source

Prolonged corticosteroid therapy and lung abnormalities in patients after severe COVID-19 pneumonia. [PDF]

Sarcoidosis Vasc Diffuse Lung Dis
Ljilja Posavec A, Cvetković Kučić D, Zagorec N, Malnar L, Lalić K, Zelenika M, Kovačevič I, Kušter D, Mutvar A, Piskač Živković N.   +9 more
europepmc   +1 more source

Drug Resistance Analysis of Pancreatic Cancer Based on Universally Differentially Expressed Genes. [PDF]

Int J Mol Sci
Xia J, Zheng L, Zhang H, Fan Q, Liu H, Wang O, Yan H.   +6 more
europepmc   +1 more source

Apolipoprotein E in Alzheimer's disease: molecular insights and therapeutic opportunities. [PDF]

Mol Neurodegener
Belaidi AA, Bush AI, Ayton S.
europepmc   +1 more source

Elderly patients are hyperresponsive to potent P2Y12 inhibitors. [PDF]

Res Pract Thromb Haemost
Mutschlechner D, Tscharre M, Wadowski PP, Lee S, Pultar J, Weikert C, Panzer S, Gremmel T.   +7 more
europepmc   +1 more source

Treatment of type II hyperlipoproteinemia with d-thyroxine

Atherosclerosis, 1976
The effectiveness of a new, almost l-thyroxine free preparation of d-thyroxine (Dynothel) was tested in 15 patients with Type IIa and 4 patients with Type IIb hyperlipoproteinemia. Eleven patients with Type IIa and 3 with Type IIb were responsive to treatment and showed an average 26% decrease in plasma TC. This decrement in plasma TC was mirrored in a
A.D. Rakow, H. U. Klör, H. Ditschuneit, E. Küter, H. H. Ditschuneit   +4 more
openaire   +4 more sources

Therapeutic failure in familial type II hyperlipoproteinemia

Metabolism, 1976
The extended use of diet and cholestyramine therapy in familial type II hyperlipoproteinemia was examined in patients who previously participated in a short-term, double-blind trial. A striking secondary failure in therapeutic response during 4 yr of use of this therapy was noted with plasma cholesterol rising an average of 15%.
Robert I. Levy, Richard S. Shulman, Peter N. Herbert, Ronald M. Krauss, Lee A. Witters   +4 more
openaire   +4 more sources

Cholestyramine in Type II Hyperlipoproteinemia

Annals of Internal Medicine, 1973
Peter O. Kwiterovich, A. K. Rider, Samuel E. Lux, W. V. Brown, Howard R. Sloan, C. J. Glueck, Neil J. Stone, Robert I. Levy, Antonio M. Gotto, Donald S. Fredrickson, J.C. LaRosa, Peter N. Herbert, T. Langer, Richard S. Shulman, David W. Bilheimer   +14 more
openaire   +4 more sources